Lexeo Therapeutics reported continued net losses for Q3 2025 (\(20.3M Q3; \)79.0M YTD), widening the Accumulated Deficit to \(359.2M. Liquidity remains robust, with \)122.8 million in cash, cash equivalents, and investments as of September 30, 2025, believed sufficient to fund operations into 2028. Operating cash burn increased year-over-year to $78.5M for the nine months ended September 30, 2025.
Financing and Capital Structure: The company secured substantial capital post-period, closing October 2025 financing transactions that provided approximately $143.9 million net proceeds, following a
...